"We expect JAK inhibitors to have widespread utility across many forms of hair loss based on their mechanism of action in both the hair follicle and immune cells," said Dr. Christiano.
"We expect JAK inhibitors to have widespread utility across many forms of hair loss based on their mechanism of action in both the hair follicle and immune cells," said Dr. Christiano.
Seventy-five percent of patients with moderate to severe alopecia areata—an autoimmune disease that causes patchy, and less frequently, total hair loss—had significant hair regrowth after treatment with ruxolitinib, reported researchers from Columbia University Medical Center (CUMC). By the end of their treatment, average hair regrowth was 92 percent.
Leave a comment: